| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855221 | INDIVIOR | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(2 years ago) | |
| US9931305 | INDIVIOR | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(2 years ago) | |
| US10285910 | INDIVIOR | Sublingual and buccal film compositions |
Oct, 2022
(1 year, 6 months ago) | |
| US8017150 | INDIVIOR | Polyethylene oxide-based films and drug delivery systems made therefrom |
Feb, 2023
(1 year, 2 months ago) | |
| US8603514 | INDIVIOR | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(17 days ago) | |
| US11135216 | INDIVIOR | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
| US9687454 | INDIVIOR | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
| US8475832 | INDIVIOR | Sublingual and buccal film compositions |
Mar, 2030
(5 years from now) | |
Suboxone is owned by Indivior.
Suboxone contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Suboxone has a total of 8 drug patents out of which 5 drug patents have expired.
Expired drug patents of Suboxone are:
- US9855221
- US9931305
- US10285910
- US8017150
- US8603514
Suboxone was authorised for market use on 30 August, 2010.
Suboxone is available in film;buccal, sublingual dosage forms.
Suboxone can be used as treating opioid use disorder, this drug is administered by sublingual route to humans for maintenance treatment of opioid dependence, treatment of opioid dependence/sublingual or buccal application.
The generics of Suboxone are possible to be released after 26 March, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 30, 2013 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL, SUBLINGUAL
SUBOXONE family patents
